Drug Type Biological products |
Synonyms |
Target |
Mechanism ANGPTL3 inhibitors(Angiopoietin like 3 inhibitors), α5β1 stimulants(Integrin alpha-5/beta-1 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 2 | US | 12 Sep 2017 | |
Osteoarthritis, Knee | Phase 2 | CZ | 12 Sep 2017 | |
Osteoarthritis, Knee | Phase 2 | DK | 12 Sep 2017 | |
Cartilage lesion | Preclinical | DK | 12 Sep 2017 | |
Cartilage lesion | Preclinical | CZ | 12 Sep 2017 | |
Cartilage lesion | Preclinical | US | 12 Sep 2017 | |
Cartilage lesion | Preclinical | DK | 12 Sep 2017 | |
Cartilage lesion | Preclinical | US | 12 Sep 2017 | |
Cartilage lesion | Preclinical | CZ | 12 Sep 2017 | |
Primary osteoarthritis of knee NOS | Preclinical | US | 16 Nov 2015 |